Adverse effects will be evaluated using physical examination according to the RTOG toxicity score, specifically for radiation-induced dermatitis. Pain will be assessed using a visual analog scale (VAS), and quality of life will be assessed using the EQ-5D-5L Thai version questionnaire. dermatitis, hyperthermia, re-irradiation
Conditions
Interventions
CT simulation of the head and neck region with 3 mm slice thickness (from vertex to carina) will be performed. Patients will be immobilized using a thermoplastic mask. Radiotherapy will be administere
Hyperthermia
Sponsors
ABEX global healthcare,Thailand
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 to 70 years. 2. Patients with recurrent squamous cell carcinoma of the head and neck, specifically cervical lymph node recurrence, after completion of standard treatment for head and neck cancer, or patients with persistent disease at the cervical region for at least 3 months after standard treatment, or newly diagnosed unresectable or chemotherapy-resistant recurrent tumors. 3.Diagnosis confirmed by radiologic imaging and/or histopathological confirmation of squamous cell carcinoma. 4. The recurrent tumor or lymph node must not exceed 10 cm in maximum diameter, and the depth from the skin surface including skin thickness must not exceed 4 cm. 5. Eastern Cooperative Oncology Group (ECOG) performance status less than 3.
Exclusion criteria
Exclusion criteria: 1. Patients with recurrent squamous cell carcinoma of the head and neck who, in the physician judgment, have the potential for curative treatment via surgery, radiotherapy, and/or chemotherapy. 2. Estimated life expectancy of less than 4 months. 3. Presence of visceral crisis, such as lymphangitic carcinomatosis, extensive liver metastases, symptomatic lung metastases, or rapidly progressive metastases. 4. Pregnant or breastfeeding women. 5. History of grade 2 or more skin toxicity from previous radiation or chemotherapy. 6.Patients with immunodeficiency, dermatologic disorders, autoimmune diseases, or conditions with a high risk of radiation dermatitis. 7. Patients receiving alternative or non-conventional cancer treatments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| volume of gross tumor at 8 weeks after end of the intervention volumetric from Computerize tomography | — |
Secondary
| Measure | Time frame |
|---|---|
| acute side effect skin toxicities during intervention RTOG radiation dermatitis grade,quality of life during intervention Patient quality of life assessed by the EQ-5D-5L Thai version questionnaire. | — |
Countries
Thailand
Contacts
Public ContactPanlop Malasri
Udonthani cancer hospital
Outcome results
None listed